<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705935</url>
  </required_header>
  <id_info>
    <org_study_id>AU011020</org_study_id>
    <nct_id>NCT04705935</nct_id>
  </id_info>
  <brief_title>Amniochorionic Membrane Cells in the Maternal Blood as a Biomarker for Preterm Birth</brief_title>
  <official_title>Amniochorionic Membrane Cells in the Maternal Blood as a Biomarker for Preterm Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARCEDI Biotech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Globally, preterm birth (15 mill. per year) is the leading cause of under-5 child mortality&#xD;
      (1 mill. per year) and morbidity. Important pathways include preterm labor contractions,&#xD;
      Preterm Prelabor Rupture of the Fetal Membranes (PPROM), and iatrogenic delivery. At labor,&#xD;
      the fetal amniochorionic membrane undergoes a cellular senescence and shed fetal&#xD;
      amniochorionic membrane cells (ACM cells) to the maternal circulation. In collaboration with&#xD;
      the private firm ARCEDI Biotech and The University of Texas Medical Branch at Galveston,&#xD;
      Aarhus University has identified specific antibodies, which can be used to isolate ACM cells&#xD;
      from maternal blood. Thus, the aim of this study is 1) to characterize ACM cells by&#xD;
      histological and immunological techniques, and 2) in a cohort assess their performance as&#xD;
      biomarkers of amniochorionic membrane dysfunction, including early detection of threatening&#xD;
      preterm birth. In perspective, the findings are expected to improve the diagnostics and&#xD;
      treatment of preterm birth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim:&#xD;
&#xD;
      The aim of the study is 1) to characterize circulating fetal amniochorionic membrane cells&#xD;
      (ACM cells) in pregnant women and 2) to investigate if they can function as biomarkers of&#xD;
      amniochorionic membrane dysfunction, including risk of preterm birth.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Globally, preterm birth (15 mill. per year) is the leading cause of under-5 child mortality&#xD;
      (1 mill. per year) and morbidity. Important pathways include preterm labor contractions&#xD;
      (PLC), Preterm Prelabor Rupture of the Fetal Membranes (PPROM), and iatrogenic delivery due&#xD;
      to preeclampsia and fetal growth restriction.&#xD;
&#xD;
      At labor, the fetal amniochorionic membrane undergoes a cellular senescence and shed fetal&#xD;
      amniochorionic membrane cells (ACM cells) to the maternal circulation. Similar features are&#xD;
      expected to be seen in cases with PPROM. In collaboration with ARCEDI Biotech Aps and the&#xD;
      University of Texas Medical Branch at Galveston, Aarhus University has identified specific&#xD;
      fetal membrane cell markers, i.e. specific proteins highly expressed by the ACM cells.&#xD;
      Commercially available antibodies specific for these identified proteins can be used to&#xD;
      isolate ACM cells from the maternal blood. The preliminary studies indicate that circulating&#xD;
      ACM cells are present in the second half of pregnancy but not in the first half of pregnancy.&#xD;
&#xD;
      The investigators want to confirm by immunohistochemistry that specific antibodies can&#xD;
      identify ACM cells in the fetal membranes, and that they can be a platform for isolating ACM&#xD;
      cells from the maternal circulation.&#xD;
&#xD;
      Materials and Methods:&#xD;
&#xD;
      The investigators will isolate ACM cells from maternal blood by Magnetic Activating Cell&#xD;
      Sorting (MACS) using different specific antibodies for ACM cells. The enriched ACM cells will&#xD;
      be stained using fluorescent-labeled cytokeratin and vimentin antibodies, and sorted&#xD;
      individually by Fluorescence Activated Cell Sorting (FACS). The true identification of the&#xD;
      fetal derived ACM cells will be done by Short Tandem Repeat (SRT) analysis.&#xD;
&#xD;
      The antibodies that perform best will be selected based on pilot studies on pregnant women at&#xD;
      term and in gestation week 12, 20, 28 and 34, as well as at labor and post partum. The&#xD;
      protein expression and specificity of each antibody will be confirmed by immunohistochemistry&#xD;
      and bright field microscopy on biopsies from the fetal membranes, placental tissue, and the&#xD;
      placental bed in the uterus.&#xD;
&#xD;
      The established protocol will be used to evaluate the number of ACM cells in the maternal&#xD;
      blood in normal and pathological pregnancies on cross sectional cohorts of term pregnant&#xD;
      women with and without labor contractions and spontaneous rupture of membranes, women with&#xD;
      PLC before 34 weeks gestation, women with PPROM before 34 weeks gestation, and a control&#xD;
      group at gestational age 25+0 to 37.&#xD;
&#xD;
      Perspectives:&#xD;
&#xD;
      In the future, the results are expected to improve the diagnostics and treatment of&#xD;
      threatening preterm birth, thus preventing mortality and morbidity in millions of children&#xD;
      worldwide.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ACM cells in maternal blood</measure>
    <time_frame>At inclusion</time_frame>
    <description>Number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>At delivery</time_frame>
    <description>Weeks+days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight of child</measure>
    <time_frame>At delivery</time_frame>
    <description>Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>At delivery</time_frame>
    <description>&lt;4, 4-7, or &gt; 7</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Preterm Premature Rupture of Membrane</condition>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Term pregnant women without labor contractions or rupture of membranes</arm_group_label>
    <description>Term pregnant women &gt; 37 weeks gestation with a normal pregnancy. One blood sample before a scheduled caesarean section.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Term pregnant women with labor contractions</arm_group_label>
    <description>Term pregnant women &gt; 37 weeks gestation with a normal pregnancy. One blood sample when labor contractions, but before spontaneous rupture of membranes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Term pregnant women with spontaneous rupture of membranes</arm_group_label>
    <description>Term pregnant women &gt; 37 weeks gestation with a normal pregnancy. One blood sample after spontaneous rupture of membranes, but without labor contractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preterm labor contractions (PLC)</arm_group_label>
    <description>One blood sample when labor contractions before 34 weeks gestation without rupture of membranes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preterm Prelabor Rupture of the Fetal Membranes (PPROM)</arm_group_label>
    <description>One blood sample when rupture of the fetal membranes before 34 weeks gestation without labor contractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Women with normal pregnancies. One blood sample in gestation week 25+0 to 37 matched as controls for PLC and PPROM cases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Longitudinal cohort during pregnancy</arm_group_label>
    <description>Women with normal pregnancies, where blood samples will be collected at week 12, 20, 28, 34 and 36, as well as at labor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Longitudinal cohort post partum</arm_group_label>
    <description>Women with normal pregnancies, where blood samples will be collected at labor, as well as 2 days, and 4, 8 and 12 weeks after birth.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women who complies to the above mentioned inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal pregnancy at term (&gt; 37 weeks) the day before a planned caesarean section.&#xD;
&#xD;
          -  Normal pregnancy at term (&gt; 37 weeks) with planned vaginal delivery.&#xD;
&#xD;
          -  Women with preterm labor contractions &lt; 34 weeks admitted at the hospital.&#xD;
&#xD;
          -  Women with PPROM &lt; 34 weeks admitted at the hospital.&#xD;
&#xD;
          -  Normal pregnancy at gestational age 25+0 to 37.&#xD;
&#xD;
          -  Normal pregnancy at gestational age 12 included at the nuchal translucency scan.&#xD;
&#xD;
          -  Normal pregnancy at birth.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Maternal age &lt; 18&#xD;
&#xD;
          -  Women who does not understand the oral or written information&#xD;
&#xD;
          -  Women who does not speak Danish&#xD;
&#xD;
          -  Women who does not want to participate&#xD;
&#xD;
          -  Women with complications in pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramkumar Menon, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Medical Branch at Galveston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torben Steiniche, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Palle Schelde, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARCEDI Biotech</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ripudaman Singh, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ARCEDI Biotech</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berthold Huppertz, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmeli Mikkelsen, MD</last_name>
    <phone>+45 29652328</phone>
    <email>emmeli.mikkelsen@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels Uldbjerg, DMSc</last_name>
    <phone>+45 20679420</phone>
    <email>uldbjerg@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmeli Mikkelsen, MD</last_name>
      <phone>+45 29652328</phone>
      <email>emmeli.mikkelsen@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Niels Uldbjerg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Amniochorionic Membrane Cells</keyword>
  <keyword>Fetal Membrane Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT04705935/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

